Neoprobe closes Biosonix deal
Two innovators of medical imaging have joined forces. Biosonix, an Israeli developer of blood flow measurement technology, is now part of Neoprobe, a maker of gamma detection systems used in the management of patients with breast cancer and melanoma. The
Two innovators of medical imaging have joined forces. Biosonix, an Israeli developer of blood flow measurement technology, is now part of Neoprobe, a maker of gamma detection systems used in the management of patients with breast cancer and melanoma. The deal that brought them together, announced Jan. 4, was closed when Neoprobe issued 9,714,737 shares of its common stock in exchange for the outstanding shares of Biosonix. An additional 2,085,826 shares of Neoprobe common stock will be issued to the Biosonix shareholders on the satisfaction of a milestone event involving Biosonix product development activity.
Biosonix products employ angle-independent Doppler blood flow technology that allows angle-independent blood flow volume and velocity readings. The technology permits real-time measurement of volume blood flow. Biosonix has three products in the late stages of development. One, FlowGuard, has received the CE mark for marketing in Europe, but none has yet passed the FDA. At the closing of the deal, Neoprobe appointed Dan Manor and Reuven Avital to its board of directors. Manor, who will remain president of Biosonix, founded the company. Avital, general manager of the investment fund Ma'Aragim Enterprises, held a large stake in Biosonix and is now a major shareholder in Neoprobe.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
What if Radiology Turns Out Exactly the Way We Predict it Will?
May 19th 2025Whether it is reimbursement cuts or continued attempts to push non-radiologist image interpretation, where do we draw the line between inspired protest and misspent energy criticizing things that are doomed to fail or things we have no control over?
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.
